CROSS-DOMAIN PATTERN
Same drug, multiple disease domains
Verteporfin appears in hypotheses across 3 disease domains: ALS, Epilepsy, Rheumatoid arthritis. Shared mediators that recur across at least two of those domains: EGFR.
Aggregated from the catalog. Biological interpretation of any multi-indication mechanism would require independent validation — this is a structural observation only.
ALL HYPOTHESES
Repurposing candidates for Verteporfin
ALS 2
| Mediator | Outcome | Score | Tier | Lit. status | Trial | |
|---|---|---|---|---|---|---|
| APP | amyotrophic lateral sclerosis | 0.269 | Mid | novel signal | none | |
| APP | MND | 0.269 | Mid | novel signal | none |
Epilepsy 2
| Mediator | Outcome | Score | Tier | Lit. status | Trial | |
|---|---|---|---|---|---|---|
| EGFR | juvenile focal epilepsies | 0.208 | Mid | novel signal | none | |
| EGFR | lesional focal epilepsy | 0.208 | Mid | novel signal | none |
Rheumatoid arthritis 1
| Mediator | Outcome | Score | Tier | Lit. status | Trial | |
|---|---|---|---|---|---|---|
| EGFR | rheumatoid arthritis | 0.269 | Mid | reproduces known | none |